Cell-free circulating tumor DNA (ctDNA) in plasma has been used as a potential noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical implications of ctDNA detection in patients with metastatic pancreatic cancer. First, we attempted to prospectively screen a panel of 60 genes in cell-free DNA (cfDNA) from ten metastatic pancreatic cancer patients via exome sequencing. Second, droplet digital PCR (ddPCR) was used to identify potential mutations in a cohort of 188 patients with metastatic pancreatic cancer. Finally, to preliminary evaluate the potential role of ctDNA in monitoring tumor responses following chemotherapy, we detected the presence of ctDNA in serial plasma samples from 13 metastatic pancreatic cancer patients (Clinical trial: NCT02017015). The analysis revealed five somatic mutations at BRCA2, EGFR, KDR and ERBB2 gene loci. The frequencies of ctDNA mutation at BRCA2, KDR, EGFR, ERBB2 exon17 and ERBB2 exon27 were 11.7%, 13.8%, 13.3%, 13.3% and 6.4% respectively. Univariate and multivariate analyses identified the ERBB2 exon17 mutation (p 5 0.035, HR 5 1.61) as an independent factor associated with overall survival among metastatic pancreatic cancer patients. Furthermore, the rate of coincident detection of ctDNA and response to treatment as assessed by CT imaging was 76.9% (10 of 13 cases), and the presence of ctDNA provided the earliest measure of treatment in 6 of 10 patients (60%). ctDNA sequencing may have clinical value for determining metastatic pancreatic cancer treatment and monitoring the tumor response.
Introduction
Pancreatic cancer is the most malignant tumor and the fourth leading cause of cancer-related death worldwide. 1 For approximately 80-85% of pancreatic cancer patients, potential curative surgery was impossible at the time of diagnosis. Gemcitabine-based chemotherapy is the standard treatment for these cases of local advanced or metastatic pancreatic cancer. However, despite the great progress of combined chemotherapy for pancreatic cancer, the 5-year survival rate of these patients remains <5%. 2,3 CA19-9 levels is frequently clinical used to predict prognosis and monitor the tumor response to therapies for pancreatic cancer. However, the CA19-9 levels in patients with biliary obstruction or infection may be abnormally elevated and may not detectable in Lewis antigen-negative individuals. 4, 5 Recently, circulating tumor cells (CTCs) have emerged as a promising biomarker, which are tumor cells that are shed from primary or metastatic sites and enter the peripheral blood. Several studies identified CTCs as a prognostic factor, whereas others reported that CTCs has no association with survival in pancreatic cancer. 6 Alterations in four "driver" genes, K-ras, CDKN2A, SMAD4 and TP53, as well as other genetic mutations have been identified in pancreatic cancer, and this evidence may provide new insight into pancreatic cancer diagnosis and therapeutic development. 7, 8 Unfortunately, nearly all of these mutations failed to facilitate a treatment approach, excluding targeted EGFR blockade, and even this therapy has little benefit. 9 The failure of currently available treatments may associated with the high proportion of stromal cells surrounding tumor cells. Furthermore, endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is invasive, and insufficient material is available for genetic analysis in approximately 15% of patients. 10 Cell-free circulating tumor DNA (ctDNA) in plasma is a noninvasive potential sample source for evaluating these issues, which is also referred to as liquid biopsy. ctDNA, which carries specific gene mutations, has been used to analyze somatic sequence alterations in various cancers through next-generation sequencing (NGS) or droplet digital polymerase chain reaction (ddPCR). 11 Recently, several studies have
shown the feasibility and clinical value of using ctDNA to screen for and detect possible genetic alterations in multiple cancers. [12] [13] [14] But few studies have investigated the clinical utility of ctDNA in pancreatic cancer. Here, we performed whole-exome sequencing of a panel of 60 genes in ten metastatic pancreatic cancer cases to select candidate genetic mutations and validated these gene mutations in a cohort of 188 metastatic pancreatic cancer patients. In addition, we used ctDNA as a noninvasive sample source to monitor metastatic pancreatic cancer treated with nab-paclitaxel plus gemcitabine chemotherapy in a prospective study (Clinical trial: NCT02017015).
Materials and Methods

Patient characteristics
All plasma samples were obtained before therapy from a total 188 metastatic pancreatic cancer patients between April 2012 and August 2014. Baseline characteristics of 188 metastatic pancreatic cancer patients were shown in Supplementary  Table S1 . These patients diagnosed based on pathology using EUS-FNA samples collected at the Department of Pancreatic Surgery, Shanghai Cancer Center. All the patients provided written informed consent, and the clinical data were obtained from electronic records. Overall survival (OS) was measured by comparing the date of diagnosis to the date of death, and the last follow-up date was April 2016. Additional serial plasma samples were collected at intervals of 8 or more weeks from 13 metastatic pancreatic cancer patients who were recruited to participate in a prospective clinical trial in our center. Computed tomography (CT) was used to evaluate the treatment response every 8 weeks according to the guidelines of Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.
DNA extraction
Plasma was separated via centrifugation at 800 g for 10 min from the ACD Vacutainer tube mentioned above, transferred to microcentrifuge tubes and centrifuged at 16,000 g for 10 min to remove cell debris. Circulating DNA was isolated from 1 to 5 ml of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, QIAGEN Strasse 1, 40724 Hilden, Germany). Briefly, buffer ACL was added into plasma and incubated in 608C, 30 min, then buffer ACB was added and incubated in 48C, 5 min. Then mixture was separated by HiPure CFDNA Mini column, and eluted by buffer TE. DNA concentration and purity were quantified using a Qubit 2.0 Fluorometer (Life Technologies, Thermo Fisher Scientific, Fremont, CA) and an Agilent 2100 Bioanalyzer (Agilent Technologies, 5301 Stevens creek blvd, Santa Clara, CA).
ctDNA mutation detection via NGS
Indexed Illumina NGS libraries were prepared from plasma DNA and whole blood. For patient plasma DNA, 10-60 ng of DNA were used for library construction without additional fragmentation. For germline DNA, 670-2600 ng of DNA were sheared before library construction using a Covaris S2 sonicator using the recommended settings for 200-bp fragments.
The NGS libraries were constructed using the SureSelectXT Reagent Kit (Agilent Technologies) according to the manufacturer's protocol. Library purity and concentration were assessed using a spectrophotometer (Qubit V R 2.0) and qPCR (Illumina Biosystems), respectively. Fragment length was determined using a 2100 Bioanalyzer using a High-Sensitivity DNA Kit (Agilent Technologies).
Hybrid selection was performed using a custom library (SureSelect, Agilent Technologies). This library was designed using the SureSelect DNA Standard Design Wizard. Input genomic regions were selected according to the genes and exons most frequently mutated in pancreatic cancer. These regions were identified from the COSMIC database, TCGA and other published sources. 8, [15] [16] [17] [18] Agilent Technologies SureSelectXT was used according to the manufacturer's protocol with modifications. Unique index tags were added to each DNA fragment during the Illumina library preparation. Following hybrid selection, the captured DNA fragments were amplified by performing 12-16 cycles of PCR using 1 of ll Herculase II Fusion DNA Polymerase and 0.5 ll of 100 mM dNTP Mix in a 50-ll reaction volume. The PCR products were then purified using Agencourt AMPure XP beads.
The libraries were analyzed using massively parallel sequencing on the HiSeq2500 platform (Illumina, San Diego, CA) with 150-bp paired reads according to the manufacturer's instructions. The average sequencing depths of the cfDNA and control genomes were approximately 5,0003, after the removal of PCR duplicates.
What's new?
We identified five somatic mutations at BRCA2, EGFR, KDR and ERBB2 gene loci. ERBB2 exon17 mutation in ctDNA was identified as an independent prognostic factor. In addition, the presence of ctDNA was associated with tumor responses, and provided the earliest measure of treatment in 6 of 10 patients (60%). Detection of ctDNA mutation may be used to guide treatment decisions, and monitor treatment responses in metastatic pancreatic cancer patients.
Paired-end reads were mapped to the hg19 reference genome using BWA 0.7.1 (default parameters), followed by sorting and indexing using SAMtools. Quality control (QC) was performed using Trimmomatic to assess a variety of parameters, including sequencing characteristics, read quality and selector on-target rate (i.e., number of unique reads that intersect the selector space divided by all aligned reads) using SAMtools flagstat, FastQC and PICARD. Plots of fragment length distribution and sequencing depth and coverage were automatically generated for visual QC assessment.
ctDNA mutation detection via ddPCR
The mutation levels of ctDNA were measured using a ddPCR system (Bio-Rad Laboratories, Hercules, CA). Briefly, primers and probes for detection of BRCA2, EGFR, KDR, ERBB2 and K-ras (Supplementary Table S4 ) were obtained following the recommended protocol (Bio-Rad Laboratories). The PCR mixture was loaded into an 8-channel, single-use consumable droplet generation cartridge. Approximately 20,000 monodispersed droplets for each sample were prepared using the QuantaLife droplet generator. The water-in-oil emulsions were pipette-transferred to a 96-well PCR plate and subjected to amplification cycles. (Cycling protocol: 958C for 10 min, 40 cycles of 948C for 30 s and 608C for 60 s, and a final step at 988C for 10 min.) Then plates were loaded into the commercially obtained QX100 droplet reader (Bio-Rad). For ddPCR determination of thresholds, when PCR monodispersed droplets had fluorescence signal, the sample had mutation and the result was positive, whereas those without fluorescence signal represent the negative. And the concentrations (copy numbers) of the targets in the samples were determined using QuantaSoft software.
Statistical analysis
Overall survival was evaluated using the Kaplan-Meier method, and the log-rank test was performed to compare survival curves. The Cox proportional hazard regression method was used to identify independent factors associated with OS. p < 0.05 was considered to indicate a significant difference. Two-category data comparisons were analyzed according to the Pearson v 2 test and the Fisher exact test. All statistical analyses were performed using the SPSS version 16.0 software package.
Results
Identification of candidate somatic genomic alterations of ctDNA in plasma via NGS
We performed NGS to examine the entire exomes of a panel of 60 hotspot genes in cfDNA and matched leukocytes from 10 metastatic pancreatic cancer patients (Supplementary  Table S2 ). To mitigate the impact of sequencing errors, analyses not involving fusions were restricted to properly paired reads, and only bases with Phred quality scores 30 (0.1% probability of a sequencing error) were further analyzed. After data analysis, SNVs were considered to be potential mutations if they met the following criteria: (1) both the ctDNA samples and the matched normal DNA samples should be covered >2,000 times at each genomic position being compared; (2) variants should be supported by at least 5% of the total reads in the ctDNA sample if no high-quality, variant-supporting reads are allowed in the normal DNA sample and (3) variants should be supported by at least 100 reads in the ctDNA sample. Ten unique nonsynonymous variants were selected within the ALK, HNF1A, BRCA2, KDR, EGFR, KMT2C, ERBB2 and ATM gene loci (Supplementary  Table S3 ). Then, we used ddPCR to further validate these ten nonsynonymous point mutations in these ten original plasma samples. Finally, five nonsynonymous alterations located in the BRCA2, KDR, EGFR, ERBB2 genes were chosen for further analysis (Fig. 1 and Supplementary Table S5 ). All of these mutations resulted in amino acid substitutions in the corresponding encoded proteins.
Detection of potentially mutated genes in a cohort of 188 metastatic pancreatic cancer patients
We further evaluated the five nonsynonymous variants in ctDNA from an additional cohort of 188 metastatic pancreatic cancer patients via ddPCR. As K-ras is the most frequently mutated gene in pancreatic cancer, we examined the K-ras (G12V, G12D and G12R) mutation in these plasma samples as a benchmark of ctDNA. Overall, we identified 289 mutations in these plasma samples. Of these 188 plasma samples, 32 samples (17%) has none mutation whereas the remaining 156 samples (83%) have baseline ctDNA with one mutation for 71 samples, two mutations for 50 samples, three mutations for 24 samples, four mutations for 9 samples and five mutations for 2 samples. The rates of BRCA2, KDR, EGFR, ERBB2 exon17 and ERBB2 exon27 mutations were 22 out of 188 samples (11.7%), 26 out of 188 samples (13.8%), 25 out of 188 samples (13.3%), 25 out of 188 samples (13.3%) and 12 out of 188 samples (6.4%), respectively. The K-ras mutation rate was 72.3% (136 out of 188 samples). The rate of Kras G12V, G12D and G12R mutations was 65 out of 188 samples (34.6%), 98 out of 188 samples (52.1%) and 17 out of 188 samples (9.0%), respectively (Table 1) .
Specific gene mutations and overall survival in metastatic pancreatic cancer
We further evaluated whether these gene mutations and clinical-pathological characteristics were associated with OS. In a cohort of 188 metastatic pancreatic cancer patients, Kaplan-Meier analysis showed that age, gender, BRCA2 mutation, KDR mutation, EGFR mutation, ERBB2 exon27 mutation, K-ras G12 mutation, K-ras G12D mutation and K-ras G12R mutation were not associated with survival. In contrast, CA19-9 and CA125 levels, chemotherapy, the number of metastatic sites, ERBB2 exon17 mutation and K-ras G12V mutation were significantly associated with OS (Fig. 2) . Moreover, we performed multivariate Cox proportional hazard regression analysis using all factors that were identified (Table 2) .
Tumor monitoring with ctDNA and other circulating biomarkers in 13 metastatic pancreatic cancer patients
To preliminary investigate whether the presence of ctDNA correlated with the response to chemotherapy, serial plasma samples from 13 metastatic pancreatic cancer patients from a clinical trial (NCT02017015) at Shanghai Cancer Center were monitored via ddPCR assays. The characteristics of these metastatic pancreatic cancer patients were shown in Supplementary Table S6 . We compared the presence of ctDNA with other biomarkers including CTC abundance and CA19-9 levels. CT was used as the gold standard for measurement of disease status (as defined by RECIST 1.0). The CA19-9 levels were available across 81 serial time points and CTC and ctDNA data were available across 66 serial time points for all 13 patients. CA19-9 levels were elevated (>37U/ml) at the time of diagnosis in 10 of the 13 (76.9%) patients (Supplementary Table S6 ). CA19-9 was generally correlated with tumor responses as assessed by CT. The presence of ctDNA, which was largely focused on the K-ras G12 mutation, was associated with tumor responses as observed on CT images in 10 of the 13 (76.9%) patients and with CTC abundance in 6 of the 13 (46.2%) patients. Furthermore, the presence of ctDNA provided the earliest measure of treatment in 6 of 10 patients (60%, three patients still lacked disease progression during the follow-up period). One patient (patient M19) carried two mutations (K-ras G12D and BRCA2) at diagnosis and generally showed similar dynamic changes over the entire course of treatment. Eight patients carried new mutations that were detected during treatment, and these mutations might be associated with tumor progression (Fig.  3, Supplementary Figs. S2 and S3 ).
Discussion
Precise individualized treatment is the novel goal for pancreatic cancer, which is mainly determined by the detection of genetic alterations. 19 The clinical application of biopsy specimens is limited within the existence of tumor heterogeneity and insufficient tumor tissues. 10 The analysis of ctDNA represents a unique method to explore the genetic mutation and may translate into the clinical arena. To our knowledge, for the first time, we identified four potential clinically Figure 1 . Study design for whole-exome sequencing and ctDNA analyses.NGS analyses were performed on cfDNA in plasma from 10 metastatic pancreatic cancer patients using whole-exome analyses focused on 60 genes. Five somatic mutations were selected for further analyses. These somatic mutations were detected by ddPCR in plasma from 188 metastatic pancreatic cancer cases before therapy for clinical analyses. In addition, serial samples from 13 metastatic pancreatic cancer patients (Clinical trial: NCT02017015) were used to detect circulating markers and to monitor tumor responses. [Color figure can be viewed at wileyonlinelibrary.com] meaningful gene mutations (BRCA2, EGFR, KDR and ERBB2) rates in ctDNA from metastatic pancreatic cancer patients. It was reported that the BRCA mutation rate in pancreatic cancer tissues was approximately 5% while other mutations in pancreatic cancer tissues are rare. 8, 20 Our data showed that the rate of BRCA2 mutation in ctDNA is 11.7% Figure 2 . Kaplan-Meier analyses of the differences in OS in 188 metastatic pancreatic cancer patients. Groups were compared using the log-rank test. [Color figure can be viewed at wileyonlinelibrary.com] in metastatic pancreatic cancer, and this gene mutation has been identified to be more sensitive for cisplatin-based chemotherapy. EGFR is overexpressed in pancreatic cancer, and this factor is associated with worse outcome. 21, 22 We found that the rate of EGFR mutation in ctDNA was 13.3%. A phase III clinical trial confirmed that combining the oral EGFR tyrosine kinase inhibitor drug erlotinib with Gemcitabine prolonged OS. 9 Therefore, patients carrying the EGFR mutation in ctDNA may benefit from EGFR tyrosine kinase inhibitor drug treatment. KDR is a receptor of vascular endothelial growth factor (VEGF), and its mutation is associated with pancreatic cancer prognosis. However, targeted therapy against VEGF combined with chemotherapy failed to show any improvement in survival among advanced pancreatic cancer patients. [23] [24] [25] In our study, we detected a KDR mutation rate in ctDNA of 13.8%. ERBB2, which is also known as HER2, is upregulated in subsets of various cancers, and its mutation is associated with tumor progression and outcome. 26 Patients with breast cancer overexpressing ERBB2 have been observed to benefit from treatment with the monoclonal antibody trastuzumab, which targets ERBB2. 27 However, a multicenter phase II clinical trial showed that trastuzumab does not improve the prognosis of metastatic pancreatic cancer. 28 Our data identified two mutation sites in ERBB2; the mutation rate of ERBB2 exon17 was 13.3%, and that of ERBB2 exon27 was 6.4%. Interestingly, univariate and multivariate analyses showed that ERBB2 exon17 mutation was negatively associated with OS among 188 metastatic pancreatic cancer patients. These patients carrying an ERBB2 mutation may be responsive to trastuzumab therapy, and further clinical trials are needed to determine whether patients carrying an ERBB2 mutation would benefit from targeted therapy using trastuzumab. Furthermore, it was well recognized that K-ras gene mutations are the most frequently observed mutations in pancreatic cancer tissues, appearing in 75%-95% of these cases. For K-ras mutation in ctDNA, several studies detected the rate of K-ras mutation in resectable and advanced pancreatic cancer with about 30% and 65%, respectively. [29] [30] [31] Our results showed that the K-ras G12 mutation rate was 72.3% in ctDNA of metastatic pancreatic cancer patients and that the K-ras G12V mutation correlated with poorer OS based on subgroup analysis. These results are consistent with those of another study. 29 Monitoring of the tumor response to various treatments via CT imaging is often delayed to reflect disease progression, as biological failure always occurs earlier than treatment failure based on imaging. The detection of ctDNA levels via the identification of somatic mutations in cancer patients is specific. ctDNA has been found to act as an earlier marker of the tumor response or disease progression following various therapies in metastatic colorectal cancers and breast cancers. 32, 33 Recently, Zill et al. reported that changes in the number of ctDNA mutations strongly correlated with changes in CA19-9 levels over the course of treatment in a group of eight advanced pancreatic cancer cases. 34 In our study, the coincidence rate of ctDNA changes and treatment responses was 76.9% (10 of 13 cases), and measurement of ctDNA predicted the earliest treatment relapse in 6 of 10 patients (60%). Mutations in ctDNA reflecting acquired resistance to targeted therapy after treatment have been identified in patients with metastatic colorectal cancer. 35 DNA fragments can be obtained from drug-resistant pancreatic cancer cells in plasma when the treatment has failed, and the failed treatment may promote genetic mutations promoting resistance to further clinical therapies as well. Detection of CTCs could lead to the routine analysis before and during Figure 3 . Comparison of ctDNA detection, CTC abundance and CA19-9 levels as factors for monitoring the tumor response.Serial measurements of ctDNA levels (copies/ml), CTC abundance (per 7.5 ml of whole blood), CA19-9 levels (U/ml) and disease status as evaluated by CT in six metastatic pancreatic cancer patients. ND, not detected; SD, stable disease; PD, progressive disease; PR, partial response. The highest measured level of CA19-9 was 1,000 U/ml. In patient M17, the levels of CA19-9 remained >1,000 throughout the course of treatment. [Color figure can be viewed at wileyonlinelibrary.com] chemotherapy. CTCs have been reported to be used as a biomarker for monitoring the response to treatment in several cancers. 36 However, in our study, changes in the abundance of CTCs did not strongly reflect changes in the response of the disease to treatment in metastatic pancreatic cancer.
One limitation of our study is that the sample size of patients used to monitor the treatment response was insufficient, with thirteen cases. Another limitation is that patients with different gene mutations did not receive precise, accurate therapy. For example, patients carrying the BRCA2 mutation were not treated with cisplatin-based therapy. In addition, this is a retrospective study, for the prognostic role of ctDNA in multivariate analyses, other parameters such as different chemotherapy regimens may influence the survival as well.
In conclusion, although the clinical utility of ctDNA as a biomarker for pancreatic cancer has not yet been determined, target gene sequencing analysis using ctDNA-based liquid biopsy samples could be performed to explore precise individualized treatments. With the advancement of ctDNA technology, this noninvasive method, which enables the collection of serial samples, will ultimately guide treatment decisions and will be used to monitor treatment responses in real time in metastatic pancreatic cancer patients.
